全文获取类型
收费全文 | 200篇 |
免费 | 6篇 |
国内免费 | 4篇 |
专业分类
儿科学 | 13篇 |
妇产科学 | 2篇 |
基础医学 | 28篇 |
口腔科学 | 7篇 |
临床医学 | 15篇 |
内科学 | 39篇 |
皮肤病学 | 2篇 |
神经病学 | 4篇 |
特种医学 | 50篇 |
外科学 | 6篇 |
综合类 | 7篇 |
预防医学 | 8篇 |
眼科学 | 3篇 |
药学 | 20篇 |
肿瘤学 | 6篇 |
出版年
2022年 | 1篇 |
2021年 | 5篇 |
2019年 | 4篇 |
2018年 | 1篇 |
2017年 | 2篇 |
2016年 | 3篇 |
2015年 | 5篇 |
2014年 | 10篇 |
2013年 | 7篇 |
2012年 | 2篇 |
2011年 | 1篇 |
2010年 | 8篇 |
2009年 | 3篇 |
2008年 | 3篇 |
2007年 | 4篇 |
2006年 | 3篇 |
2005年 | 10篇 |
2004年 | 7篇 |
2003年 | 5篇 |
2002年 | 4篇 |
2001年 | 1篇 |
1999年 | 3篇 |
1998年 | 14篇 |
1997年 | 13篇 |
1996年 | 16篇 |
1995年 | 8篇 |
1994年 | 8篇 |
1993年 | 15篇 |
1992年 | 3篇 |
1991年 | 2篇 |
1990年 | 3篇 |
1989年 | 9篇 |
1988年 | 5篇 |
1987年 | 3篇 |
1986年 | 2篇 |
1985年 | 3篇 |
1984年 | 2篇 |
1983年 | 4篇 |
1981年 | 1篇 |
1980年 | 2篇 |
1979年 | 1篇 |
1977年 | 2篇 |
1976年 | 2篇 |
排序方式: 共有210条查询结果,搜索用时 31 毫秒
201.
202.
Diaphanography as a means of detecting breast cancer 总被引:1,自引:0,他引:1
203.
LT Goodnough ; TH Price ; KD Friedman ; M Johnston ; D Ciavarella ; N Khan ; R Sacher ; WR Vogler ; M Wissel ; RI Abels 《Transfusion》1994,34(1):66-71
BACKGROUND: Previous clinical trials have shown that the use of recombinant human erythropoietin (EPO) can facilitate autologous blood donation and reduce allogeneic blood transfusions in autologous blood donors who are anemic at first donation. However, the role of EPO therapy in nonanemic patients remains undefined. To identify this role, a randomized, controlled, multicenter dose-escalation trial was conducted in patients whose initial hematocrit was > 39 percent (0.39). STUDY DESIGN AND METHODS: EPO (150, 300, or 600 units/kg) or placebo was administered intravenously at each of six phlebotomy visits over a 3-week study period. Sixteen (14%) of 116 patients were unable to complete the treatment protocol because of adverse events (n = 11) or for personal reasons (n = 5); 2 patients (1 EPO and 1 placebo) experienced serious adverse events. RESULTS: In 91 evaluable patients, additional red cell production during the study period was 440 +/− 176, 621 +/− 215, 644 +/− 196, and 856 +/− 206 mL (mean +/− SD), respectively, for patients receiving placebo and EPO at 150, 300, and 600 units/kg (p < 0.05 for all EPO groups compared to placebo). However, the percentages of patients in each group who received allogeneic blood did not differ: 2 (9%) of 23 placebo patients and 6 (9%) of 68 EPO patients. CONCLUSION: It is concluded that, while EPO therapy increased preoperative red cell production, no clinical benefit could be demonstrated in autologous blood donors who were not anemic at first blood donation. 相似文献
204.
205.
206.
Childhood acute myeloid leukemia (AML) has a poor prognosis with standard chemotherapy. Allogeneic bone marrow transplantation (BMT) in remission improves the outlook only for the one third of patients with sibling donors. Autologous BMT with a lower morbidity and mortality is available to all. In this study, maximum cytoreduction was achieved by intensive early chemotherapy. Final intensification, with autologous BMT was offered to all those remaining in first complete remission (CR). Patients received two induction and two consolidation courses of intensively scheduled chemotherapy. Cytoreduction was assessed on day 14 and remission was assessed after courses 2 and 4. Bone marrow was harvested after recovery from the second consolidation course or after the first maintenance course and separated on a discontinuous percoll gradient before cryopreservation. Twenty-eight of 31 consecutively enrolled patients achieved CR. Three relapsed early and, of the 25 eligible, 24 underwent autologous BMT. Twenty-three patients received high-dose melphalan and 1 received busulphan and cyclophosphamide before autologous BMT at a median of 113 days (range, 86 to 301) after initial CR. Trilineage engraftment occurred in all. Neutrophil recovery to greater than 0.5 x 10(9)/L occurred at a median of 46 days (range, 13 to 92) after autologous BMT. Platelet recovery was delayed, with a median time to achieve greater than 20 x 10(9)/L of 42 days (range, 18 to 215). With a minimum follow up of 25 months following autologous BMT only 3 children have relapsed. The 5-year event-free survival rate (EFS) from diagnosis is 68% (95% confidence interval, 46% to 90%). Five- year EFS following autologous BMT is 87% (95% confidence interval, 67% to 100%). Autologous BMT with high-dose melphalan administration after intensive chemotherapy has produced EFS equivalent to allogeneic BMT and is associated with a strikingly low relapse rate. High-dose melphalan appears to be a valuable agent for conditioning therapy in AML. 相似文献
207.
Tujin Shi Thomas L. Fillmore Xuefei Sun Rui Zhao Athena A. Schepmoes Mahmud Hossain Fang Xie Si Wu Jong-Seo Kim Nathan Jones Ronald J. Moore Ljiljana Pa?a-Toli? Jacob Kagan Karin D. Rodland Tao Liu Keqi Tang David G. Camp II Richard D. Smith Wei-Jun Qian 《Proceedings of the National Academy of Sciences of the United States of America》2012,109(38):15395-15400
Sensitive detection of low-abundance proteins in complex biological samples has typically been achieved by immunoassays that use antibodies specific to target proteins; however, de novo development of antibodies is associated with high costs, long development lead times, and high failure rates. To address these challenges, we developed an antibody-free strategy that involves PRISM (high-pressure, high-resolution separations coupled with intelligent selection and multiplexing) for sensitive selected reaction monitoring (SRM)–based targeted protein quantification. The strategy capitalizes on high-resolution reversed-phase liquid chromatographic separations for analyte enrichment, intelligent selection of target fractions via on-line SRM monitoring of internal standards, and fraction multiplexing before nano–liquid chromatography-SRM quantification. Application of this strategy to human plasma/serum demonstrated accurate and reproducible quantification of proteins at concentrations in the 50–100 pg/mL range, which represents a major advance in the sensitivity of targeted protein quantification without the need for specific-affinity reagents. Application to a set of clinical serum samples illustrated an excellent correlation between the results obtained from the PRISM-SRM assay and those from clinical immunoassay for the prostate-specific antigen level. 相似文献
208.
209.
210.